Spread of health misinformation by health professionals who also hold government positions represents a long-standing problem exacerbated during the COVID-19 pandemic.
AMA J Ethics. 2023; 25(3):E210-218. doi:
10.1001/amajethics.2023.210.
Isabelle Freiling, PhD, Nicole M. Krause, MA, and Dietram A. Scheufele, PhD
Misinformation is an urgent new problem, so health professions communities need solutions as much as they need to be wary of ethical pitfalls of rushed interventions.
AMA J Ethics. 2023; 25(3):E228-237. doi:
10.1001/amajethics.2023.228.
Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
AMA J Ethics. 2022; 24(11):E1040-1048. doi:
10.1001/amajethics.2022.1040.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022; 24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022; 24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.
Dr Kimberly A. Singletary joins Ethics Talk to discuss her article, coauthored with Dr Marshall H. Chin: “What Should Antiracist Payment Reform Look Like?”